Skip Navigation


European Heart Journal Advance Access originally published online on April 23, 2008
European Heart Journal 2008 29(10):1221-1223; doi:10.1093/eurheartj/ehn185
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/10/1221    most recent
ehn185v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Empana, J.-P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Empana, J.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun

Jean-Philippe Empana*

INSERM U909, Cardiovascular Epidemiology and Sudden Death, Hopital Paul Brousse, 16 Avenue Paul Vaillant Couturier, Villejuif, France

* Corresponding author. Tel: +33 1 45 59 51 00, Fax: +33 1 45 59 51 94, Email: empana@vjf.inserm.fr

This editorial refers to ‘Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease’{dagger}, by M. von Eynatten et al., on page 1307

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

{dagger} doi:10.1093/eurheartj/ehn135 Back

The first 10% of the full text of this article appears below.

Adiponectin, also known as Acrp30, AdipoQ, or gelatin-binding protein of 28 kDa (GBP28), is a hormone secreted exclusively by adipocytes.1 Since its discovery in 1995, adiponectin has been the centre of intense debate regarding its prognostic significance for coronary heart disease (CHD) in healthy populations (primary prevention) and in coronary patients (secondary prevention). This is partly due to the apparent paradox between experimental data suggesting a vascular protective effect, and epidemiological evidence failing to confirm this effect and even suggesting an increased risk in some high-risk groups. However, a new research step has just been reached since it is now possible to measure accurately adiponectin isoforms and the high molecular weight (HMW) isoform in particular. This leads to reconsideration of . . . [Full Text of this Article]

Epidemiological evidence of the link between adiponectin and cardiovascular disease

Total adiponectin
Isoforms of adiponectin
HMW isoform and cardiovascular disease
The present study in perspective

What does this study add?
What remains to be done?

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease
Maximilian von Eynatten, Andreas Hamann, Dorothee Twardella, Peter P. Nawroth, Hermann Brenner, and Dietrich Rothenbacher
EHJ 2008 29: 1307-1315. [Abstract] [Full Text]